{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:05:34Z","timestamp":1759777534258,"version":"3.40.5"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Major new drugs creation, Major science, and technology program, Sub-project of \u201cChongqing Drug Innovation Incubator Base\u201d","award":["2010ZX09401-306-2-17"],"award-info":[{"award-number":["2010ZX09401-306-2-17"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010term use of corticosteroids or local use of tazarotene (TAZ) alone for the treatment of psoriasis cause safety issues and low compliance rates. Combining these two may optimize their efficacy and minimize safety concerns. This study aimed to evaluate the clinical efficacy and safety of a fixed combination of TAZ 0.05% and betamethasone dipropionate 0.05% (BM) for psoriasis vulgaris. A multicenter, randomized, single\u2010blinded, controlled phase 3 clinical trial was conducted. A total of 600 Chinese subjects with psoriasis vulgaris were randomized (3:1:1) to TAZ\/BM cream, TAZ gel or BM cream groups for 6\u00a0weeks with an 8\u2010week follow up. The primary efficacy assessment end\u2010point was 75% improvement in Psoriasis Area and Severity Index (PASI\u201075) at 6\u00a0weeks. Secondary outcome assessments included PASI\u201090, percentage of PASI decrease and so forth. Safety and treatment\u2010related adverse events were monitored throughout the study. Our results demonstrated that the TAZ\/BM group exhibited statistically significant superiority in PASI\u201075 over TAZ (6.74% vs 1.67%) within 2\u00a0weeks. After 6\u00a0weeks of treatment, PASI\u201075 was 44.94% in the TAZ\/BM group while 19.17% and 35.00% in the TAZ and BM group, respectively. At the 8\u2010week follow up, the relapse rate of the TAZ\/BM group was significantly lower than the BM group (10.62% vs 29.63%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0269) though comparable with the TAZ group (10.00%). The most frequently reported treatment\u2010related adverse event was mild to moderate level of skin irritation events. TAZ\/BM combination has significant advantages over TAZ, including satisfying efficacy, rapid onset and reduced local stimulation. Meanwhile, compared with BM, it has the advantages of longer relief time and reduced clinical relapse rate. The TAZ\/BM combination drug provides psoriatic patients an alternative drug with high efficacy and low relapse rate and safety concerns.<\/jats:p>","DOI":"10.1111\/1346-8138.15349","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T06:15:24Z","timestamp":1588140924000},"page":"728-734","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial"],"prefix":"10.1111","volume":"47","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[{"name":"Pathology Department Institute of Dermatology and Hospital for Skin Diseases Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-9747","authenticated-orcid":false,"given":"Jianfang","family":"Sun","sequence":"additional","affiliation":[{"name":"Pathology Department Institute of Dermatology and Hospital for Skin Diseases Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhen","family":"Yang","sequence":"additional","affiliation":[{"name":"Dermatology &amp; STD Peking University First Hospital Peking China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuning","family":"Sun","sequence":"additional","affiliation":[{"name":"Dermatology Department Peking Union Medical College Hospital Peking China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Dermatology Department Peking University People\u2019s Hospital Peking China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[{"name":"Dermatology Department Changhai Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Wen","sequence":"additional","affiliation":[{"name":"Dermatology Department Shanghai Changzheng Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Dermatology Department Zhong Shan Hospital Fudan University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Liu","sequence":"additional","affiliation":[{"name":"Dermatology Department The University of Hong Kong\u2010Shenzhen Hospital Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilan","family":"Yang","sequence":"additional","affiliation":[{"name":"Dermatology Department General Hospital of Southern Theater of the Command Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Nanjing Medical University Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.007"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364351"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.844314"},{"key":"e_1_2_7_9_1","first-page":"945","article-title":"Adrenal suppression with chronic topical corticosteroid use in psoriasis patients","volume":"15","author":"Lam LH","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01067-7.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.103"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855050-00008"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01167.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70008-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01234.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"volume-title":"In Guideline on clinical investigation of medicinal product indicated for the treatment of psoriasis","year":"2004","author":"Evaluation of Medicines for Human Use","key":"e_1_2_7_17_1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90225-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70066-4"},{"key":"e_1_2_7_20_1","first-page":"15","article-title":"Safety and efficacy of a Halobetasol 0.01%\/Tazarotene 0.045% fixed combination lotion in the treatment of moderate\u2010to\u2010severe plaque psoriasis: A comparison with halobetasol propionate 0.05%","volume":"11","author":"Bhatia ND","year":"2018","journal-title":"Cream. J Clin Aesthet Dermatol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.040"},{"key":"e_1_2_7_22_1","first-page":"11","article-title":"Halobetasol 0.01%\/Tazarotene 0.045% fixed\u2010combination lotion in the treatment of plaque psoriasis: Sensitization and irritation potential","volume":"12","author":"Del Rosso JQ","year":"2019","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.15349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15349","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T13:03:19Z","timestamp":1693746199000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/1346-8138.15349"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15349","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"type":"print","value":"0385-2407"},{"type":"electronic","value":"1346-8138"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"2019-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}